Scinvivo believes that the current bladder cancer diagnostics can be improved with new imaging technologies.
Therefore, Scinvivo develops an imaging catheter which allows the urologist to visualize the bladder wall structure. The catheter works with Optical Coherence Tomography (OCT) to provide cross-sectional images of the bladder wall tissue. Current diagnostic methods are suboptimal, as the urologist has to base his decision on incomplete visual information. This leads to the fact that over 30% of the surgeries performed are unnecessary.
With the extra visual information provided by the Scinvivo catheterm the urologist can see what happens inside the bladder wall and improve the diagnosis. This leads to less uncessary surgeries and an improved quality of life for patients.
Scinvivo solves unmet needs for Payers, Patients and Doctors
Scinvivo’s imaging catheter provides real time, cross-sectional, in depth tissue images. The Optical Coherence Tomography (OCT) catheter will enable a novel clinical practice in bladder cancer research and diagnostics. By using the catheter during cystoscopy the urologist will see the tissue under the bladder wall surface, thereby providing a more accurate diagnosis. Instead of just seeing a suspicious bit of tissue with a cystoscope image, the OCT catheter will provide cross-sectional, real-time images of the bladder wall. These images will help the urologist to determine if a tumour is growing at that spot, and how deep it has grown into the bladder wall. If the tumor is superficial the treatment method is completely different compared to when the tumor has grown into the muscle layer of the bladder wall. The OCT-catheter will improve the diagnosis as less biopsies and unnecessary interventions are needed.
The imaging catheter works using Optical Coherence Tomography (OCT), which is a technology analogous to ultrasound, but uses photonics instead of soundwaves. Using light enables a very high resolution (1-50 µm) over a depth range of 3mm. The catheter uses innovative micro electric mechanical system (MEMS) mirror technology to create a laser scanner that scans the suspicious tissue.
The product is in development. All individual catheter parts are tested and now combined into a 2.5 mm outer diameter catheter. Alongside, adjustments and improvements for the second generation catheter are in development. The first in vivo clinical pilot test are expected in 2021.
Maaike de Jong started to work on the development of the Scinvivo catheter in December 2015. She worked fulltime on this project as a part of her PDEng degree Design and Technology of Instrumentation. Maaike has a background in Biomedical Engineering and obtained her Bachelor degree at Eindhoven University of Technology, and her Master degree at Delft University of Technology. She obtained her professional doctorate in engineering (PDEng) at Eindhoven university of Technology. At the beginning of 2017, Maaike spend a five month internship in Boston at Massachusetts General Hospital to specialize in Optical Coherence Tomography and its endoscopic applications. Since September 2017, she works fulltime for Scinvivo.
Marijn van Os will take the role of CEO, starting October 1st 2019. Marijn founded Scinvivo in 2016. As entrepreneur he also started Innoluce in 2010 as a spin-off of Royal Philips and Marijn successfully managed the acquisition of Innoluce by Infineon in 2016. After his PhD in mechanical engineering (TU Twente) Marijn started his career at Philips as technologist, later he joined Philips Display Components for building a new CRT factory, where he was responsible for commissioning equipment, processes and production lines. Prior to founding Innoluce Marijn was development manager at Philips Applied Technologies. After the acquisition of Innoluce Marijn took the site managers role to further grow the development centre for Infineon in The Netherlands.
Camile van der Heijden joined Scinvivo fulltime in November 2018, to work on the design of the next generation Scinvivo catheter, specializing in improving the electronics. He also investigates other markets aside from bladder cancer.
Camile first started his work at Scinvivo in June 2018, with a project as part of his post-master traineeship Qualified Medical Engineer at the Stan Ackermans Institute. During this 3-month project he investigated which application held the most potential for Scinvivo after bladder cancer diagnostics. For the rest of his traineeship, Camile was employed at the Maxima Medical Center. There he worked on designing an improved educational simulation environment for use during training of the Neonatal Invasive Care Staff, for which he ultimately received a professional doctorate in engineering (PDEng.) degree. Previous education includes a Bachelor’s degree in Biomedical Engineering and a Master’s degree in Medical Engineering, both received at the Eindhoven University of Technology.
Medical Imaging Engineer
Malak Aljourishi started working full-time in Scinvivo in August 2020 as a medical imaging engineer. Her role is to implement image processing algorithms for OCT data acquired by Scinvivo catheter. She contributes to the design of graphical user interface for clinical specialists.
Malak studied Biomedical engineering and obtained her master degree from University of Applied Sciences Jean-Germany. Image processing was an essential part of her master’s thesis at Biomedical Engineering and Physics department in Academic Medical Center (AMC).
We would be happy to tell you more about our products
Paasheuvelweg 25 Wing 5C Amsterdam
+31 6 36054746